Dennis Cho Sells 348 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 348 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $165.49, for a total value of $57,590.52. Following the transaction, the insider directly owned 73,303 shares of the company’s stock, valued at $12,130,913.47. This represents a 0.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Tuesday, September 8th, Dennis Cho sold 412 shares of Twist Bioscience stock. The stock was sold at an average price of $122.62, for a total transaction of $50,519.44.

Twist Bioscience Stock Performance

NASDAQ TWST traded down $6.10 during midday trading on Wednesday, hitting $158.50. The company had a trading volume of 2,133,311 shares, compared to its average volume of 1,563,605. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $170.66. The stock has a market cap of $9.94 billion, a price-to-earnings ratio of -71.40 and a beta of 2.22. The firm has a fifty day simple moving average of $121.94 and a two-hundred day simple moving average of $84.72. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same period last year, the company earned $0.33 EPS. The company’s revenue was up 23.2% on a year-over-year basis. Equities analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after purchasing an additional 185 shares during the period. Allworth Financial LP grew its position in shares of Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock worth $62,000 after buying an additional 213 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after buying an additional 453 shares during the last quarter. Trifecta Capital Advisors LLC acquired a new position in Twist Bioscience in the second quarter valued at approximately $63,000. Finally, Intech Investment Management LLC boosted its stake in Twist Bioscience by 2.6% in the fourth quarter. Intech Investment Management LLC now owns 25,477 shares of the company’s stock valued at $808,000 after acquiring an additional 643 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TWST. Robert W. Baird raised their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Leerink Partners lifted their target price on shares of Twist Bioscience from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Thursday, September 17th. Evercore cut Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a report on Monday, July 6th. Guggenheim reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 24th. Finally, UBS Group assumed coverage on Twist Bioscience in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $103.00.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.